

Special Issue

Metabolic Cancer Therapy: Targeting Tumor Metabolism for Innovative Adjuvant Treatment

Message from the Guest Editor

A possible emerging approach to cancer treatment involves the targeting of aberrant tumor metabolism. The metabolic changes that occur throughout the progression of cancer provide distinct characteristics that can be used for therapeutic purposes, specifically targeting the metabolic demands of neoplastic cells for essential nutrients. This Special Issue will explore the therapeutic possibilities that emerge from cancer-disrupted metabolism and metabolic communication, acting through nutritional, metabolic, and pharmaceutical approaches, to precisely target abnormal tumor metabolism.

Guest Editor

Dr. Raffaele Ivan Cincione

Department of Clinical and Experimental Medicine, Faculty of Medicine and Surgery, University of Foggia, Foggia, 71122 Puglia, Italy

Deadline for manuscript submissions

closed (30 September 2024)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.1
Indexed in PubMed



mdpi.com/si/194858

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.1
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-
Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).